dr. mcdermott on immotion150 trial in rcc
Published 7 years ago • 93 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
1:01
dr. mcdermott on lessons from the immotion150 trial in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
26:44
[olga zimmermannova] restoring tumor immunogenicity with dendritic cell reprogramming
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
8:28
adrenal neoplasm | @medvarsityonlineltd
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:05:38
watch drs. choueiri, mcdermott, and tannir, discuss the latest in rcc: https://bit.ly/3n3x59m
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
0:45
dr. mcdermott on the role of vegf targeted therapy in rcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
6:02
second and third-line decisions in rcc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc